Literature DB >> 29265175

Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.

H-J Weng1, T-S Wang1,2, T-F Tsai1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29265175     DOI： 10.1111/bjd.16252

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  4 in total

1.  The Inflammatory Factor SNP May Serve as a Promising Biomarker for Acitretin to Alleviate Secondary Failure of Response to TNF-a Monoclonal Antibodies in Psoriasis.

Authors:  Lanmei Lin; Yilun Wang; Xiaonian Lu; Tianxiao Wang; Qunyi Li; Runnan Wang; Jinfeng Wu; Jinhua Xu; Juan Du
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

Review 2.  Targeted Treatment for Erythrodermic Psoriasis: Rationale and Recent Advances.

Authors:  Shuai Shao; Gang Wang; Emanual Maverakis; Johann E Gudjonsson
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

3.  Clinical Features and Genetic Polymorphism in Chinese Patients with Erythrodermic Psoriasis in a Single Dermatologic Clinic.

Authors:  Yang Lo; Hsien-Yi Chiu; Tsen-Fang Tsai
Journal:  Mol Diagn Ther       Date:  2020-02       Impact factor: 4.074

4.  Erythrodermic psoriasis and palmoplantar hyperkeratosis successfully treated with secukinumab: a case report.

Authors:  Martino Carriero
Journal:  Drug Target Insights       Date:  2022-03-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.